Corvus Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
This SDG assessment for Corvus Pharmaceuticals Inc indicates the company's transparency towards the United Nations SDGs. The analysis of Corvus Pharmaceuticals Inc was assembled by All Street Sevva using leading artificial intelligence. This analysis of Corvus Pharmaceuticals Inc leverages data from across the web as well as from available filings by Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.5; made up of an environmental score of 2.7, social score of 4.8 and governance score of 6.0.
4.5
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
852 | Vaccibody AS | 4.6 | High |
852 | argenx SE | 4.6 | High |
868 | Corvus Pharmaceuticals Inc | 4.5 | High |
868 | CARsgen Therapeutics Holdings Ltd | 4.5 | High |
868 | Boiron SA | 4.5 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Corvus Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Corvus Pharmaceuticals Inc disclose current and historical energy intensity?
Does Corvus Pharmaceuticals Inc report the average age of the workforce?
Does Corvus Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Corvus Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Corvus Pharmaceuticals Inc disclose cybersecurity risks?
Does Corvus Pharmaceuticals Inc offer flexible work?
Does Corvus Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Corvus Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Corvus Pharmaceuticals Inc conduct supply chain audits?
Does Corvus Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Corvus Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Corvus Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Corvus Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Corvus Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Corvus Pharmaceuticals Inc disclose water use targets?
Does Corvus Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Corvus Pharmaceuticals Inc have a product recall in the last two years?
Does Corvus Pharmaceuticals Inc disclose incidents of discrimination?
Does Corvus Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Corvus Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Corvus Pharmaceuticals Inc disclose parental leave metrics?
Does Corvus Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Corvus Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Corvus Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Corvus Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Corvus Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Corvus Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Corvus Pharmaceuticals Inc involved in embryonic stem cell research?
Does Corvus Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Corvus Pharmaceuticals Inc disclose its waste policy?
Does Corvus Pharmaceuticals Inc report according to TCFD requirements?
Does Corvus Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Corvus Pharmaceuticals Inc disclose energy use targets?
Does Corvus Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Corvus Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Corvus Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.